Alzheimer's Disease and Other Disorders Associated With Dementia

Background: The aim of this guideline concerning therapy of dementia is to present a peer-reviewed, evidence-based statement in order to guide the practice of neurologists, geriatricians, psychiatrists, and other specialized physicians responsible for the care of patients with dementia. The main focus is the therapy of Alzheimer’s disease, but many of the recommendations apply to dementia disorders in general. Methods: The material is derived from revised EFNS guidelines and it is assembled with current findings and notations particular to Czech specifications. Evidence from original research reports, meta-analysis, and systematic reviews, published before January 2007 was considered in the writing the guidelines. Results: The task in writing this guideline proposes recommended treatment for Alzheimer’s disease, vascular dementia, Parkinson’s disease dementia, and dementia with Lewy Bodies. It also contains information about monitoring treatment, as well as treatment of behavioural and psychological symptoms in dementia. Conclusion: This guideline may contribute to the rational therapy proceeding in the most common dementia disorders according to evidence-based medicine. K. Sheardová, J. Hort, R. Rusina, A. Bartoš, V. Línek, P. Ressner, I. Rektorová za Sekci kognitivní neurologie České neurologické společnosti ČLS JEP 1 I. neurologická klinika LF MU, FN U sv. Anny, Brno 2 Neurologická klinika 2. LF UK, FN Motol, Praha 3 Neurologická klinika FTN a IPVZ, Praha 4 Neurologická klinika 3. LF UK, FN Královské Vinohrady, Praha a Psychiatrické centrum Praha 5 Neurologická klinika 1. LF, VFN, Praha 6 Neurologické oddělení, Nemocnice s poliklinikou v Novém Jičíně MUDr. Kateřina Sheardová I. NK LF MU a FN U sv. Anny Pekařská 53, 656 91 Brno tel. 543 182 645 e-mail: ksheard@sendme.cz Materiál vychází z EFNS guidelines [1] a je doplněn o některé aktuální poznatky a zmínky o českých specificích. proLékaře.cz | 10.7.2020

[1]  J. Avorn,et al.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.

[2]  E. Perry,et al.  Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial , 2000, International journal of geriatric psychiatry.

[3]  Kristine Yaffe,et al.  Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.

[4]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[5]  G. Wilcock,et al.  Long‐term efficacy and safety of galantamine in patients with mild‐to‐moderate Alzheimer's disease: multicenter trial , 2004, European journal of neurology.

[6]  A. Spector,et al.  Aspirin for vascular dementia. , 2000, The Cochrane database of systematic reviews.

[7]  J. Birks,et al.  Ginkgo biloba for cognitive impairment and dementia. , 2007, The Cochrane database of systematic reviews.

[8]  L. Candelise,et al.  Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment , 2007, Neuroepidemiology.

[9]  D. Spencer,et al.  Practice parameter: Temporal lobe and localized neocortical resections for epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons , 2003, Neurology.

[10]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[11]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[12]  B. Winblad,et al.  3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy , 2006, Dementia and Geriatric Cognitive Disorders.

[13]  B. Sahakian,et al.  Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial , 2004, Psychopharmacology.

[14]  K. Laake,et al.  Statins for the prevention of Alzheimer's disease. , 2001, The Cochrane database of systematic reviews.

[15]  L. Wilkins.  Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.

[16]  S. Salloway,et al.  Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial , 2003, Stroke.

[17]  C. Cotman,et al.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. , 2000, JAMA.

[18]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[19]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[20]  L. Schneider,et al.  Galantamine for Alzheimer's disease and mild cognitive impairment. , 2006, The Cochrane database of systematic reviews.

[21]  R. Petersen,et al.  Mild cognitive impairment , 2006, The Lancet.

[22]  Günther Deuschl,et al.  Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.

[23]  B. Oken.  Practice parameter: Management of dementia (an evidence-based review) , 2001, Neurology.

[24]  A. Bava,et al.  Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms , 2002, European Neurology.

[25]  D. Craig,et al.  Galantamine for vascular cognitive impairment. , 2006, The Cochrane database of systematic reviews.

[26]  P Dal-Bianco,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[27]  K. Yaffe,et al.  Hormone replacement therapy to maintain cognitive function in women with dementia. , 2002, The Cochrane database of systematic reviews.

[28]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. , 1996, Dementia.

[29]  F. Sherriff,et al.  Memantine for dementia. , 2005, The Cochrane database of systematic reviews.

[30]  A. Wallin,et al.  The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia , 2000, Journal of the Neurological Sciences.

[31]  Dag Aarsland,et al.  Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies , 2004, Journal of geriatric psychiatry and neurology.

[32]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[33]  J. O’Brien,et al.  Treating behavioural and psychological signs in Alzheimer's disease , 1999, BMJ.

[34]  J. Cummings,et al.  Assessment and Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease , 2004 .

[35]  I. McKeith,et al.  Behavioural changes and psychological symptoms in dementia disorders , 2005, The Lancet Neurology.

[36]  L. Thal,et al.  A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. , 2000, Neurology.

[37]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[38]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[39]  L. Schneider,et al.  Estrogen levels do not correlate with improvement in cognition. , 2003, Archives of neurology.

[40]  Šimon Scharf,et al.  A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease , 1999, Neurology.

[41]  C. Callahan,et al.  The Efficacy of Pentoxifylline in the Treatment of Vascular Dementia: A Systematic Review , 2003, Alzheimer disease and associated disorders.

[42]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[43]  Jan A Staessen,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.

[44]  P. Scheltens,et al.  Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline , 2007, European journal of neurology.

[45]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[46]  C. Lines,et al.  Rofecoxib , 2004, Neurology.